J&J Medical Connect
DARZALEX®

(daratumumab)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

DARZALEX - Pharmacokinetics

Last Updated: 10/28/2026

Summary

  • For complete product information that is relevant to this topic, please refer to the approved labeling.
  • Simulation of daratumumab pharmacokinetics (PK) was conducted for all recommended dosing schedules using individual PK parameters of patients with multiple myeloma (n=1309). The simulation results confirmed that the split and single dosing for the first dose should provide similar PK, with the exception of the PK profile in the first day of treatment.1
  • Clemens et al (2015, 2017)2,3 reported a PK analysis of the GEN501 and SIRIUS studies, evaluating IV daratumumab monotherapy in patients with relapsed/refractory multiple myeloma (MM) who had received proteasome inhibitors (PIs) and/or immunomodulatory agents.
    • Yan et al (2015)4 reported the results of a population pharmacokinetic (PPK) model showing that daratumumab clearance was concentration- and time-dependent and that nonlinear clearance decreased over time.
  • Xu et al (2016, 2018)5,6 conducted PPK and exposure-response analyses for daratumumab in combination with standard therapies for multiple myeloma in patients previously treated with 1 or more lines of therapy. The PK of daratumumab were similar between the monotherapy and combination therapy studies.
  • Xu et al (2018, 2020)7,8 reported PK findings utilizing data collected from the phase 1b MMY1001 study as well as evaluated PPK simulations of daratumumab split first dose and single first dose dosing regimens for daratumumab monotherapy and various daratumumab combination dosing schedules. Except for the first day of treatment, similar PK data was observed when comparing daratumumab split first dose and single first dose regimens using the PK data from MMY1001 as well as the PPK simulation analysis across multiple indications and combination dosing schedules.

BACKGROUND

The exact mechanism by which daratumumab is cleared from the human body is unknown. As an IgG1қ monoclonal antibody, daratumumab is presumably biotransformed in the same manner as any other endogenous IgG (degraded into small peptides and amino acids via catabolic pathways), and is subject to similar elimination.9,10 Renal excretion and hepatic enzyme-mediated metabolism of intact daratumumab are therefore unlikely to represent major elimination routes.11

pHARMACOKINETIC STUDIES

GEN501 and SIRIUS Pharmacokinetic Analysis

Clemens et al (2015, 2017)2,3 evaluated the PK of IV daratumumab monotherapy in patients with multiple myeloma relapsed from or refractory to prior (PIs) and/or immunomodulatory agents who participated in the GEN501 and SIRIUS studies (N=223).

Study Design/Methods

  • GEN501 was a phase 1/2, open-label, multicenter study.
    • The study consisted of a dose-escalation phase (part 1) and a single-arm, dose-expansion phase at 2 dose levels (part 2).
      • In part 1 (n=32), sequential cohorts of patients received daratumumab 0.005 to 24 mg/kg.
        • There was a 3-week washout period after the first infusion, then doses were administered weekly up to 7 full infusions.
        • Predoses (10% of the full dose and ≤10 mg) were administered a day prior to the first 2 full infusions.
      • In part 2 (n=72), patients received either:
        • Daratumumab 8 mg/kg weekly for 8 weeks, every 2 weeks for 16 weeks, and monthly until disease progression (n=30), or
        • Daratumumab 16 mg/kg for the first infusion followed by a 3-week washout period, then weekly for 7 weeks, every 2 weeks for 14 weeks, and then monthly until disease progression (n=42)
    • Patients had documented myeloma requiring systemic therapy, an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2 and had relapsed from or were refractory to ≥2 prior therapies, including PIs, immunomodulatory agents, chemotherapy, or autologous stem-cell transplantation.
    • There were 104 patients enrolled in the study, 100 of whom were evaluable for PK.
  • SIRIUS was an open-label, international, multicenter study.
    • Patients received either:
      • Daratumumab 8 mg/kg every 4 weeks (n=18), or
      • Daratumumab 16 mg/kg weekly for 8 weeks, every 2 weeks for 16 weeks, and monthly thereafter (n=106)
    • Patients had documented myeloma with disease progression on their most recent line of therapy, an ECOG PS ≤2, and had received ≥3 lines of prior therapies, including a PI and an IMiD, or were refractory to both a PI and an IMiD.
    • There were 124 patients enrolled in the study, 123 of whom were evaluable for PK.
  • Noncompartmental analysis and PPK modeling were conducted to characterize the PK of daratumumab.
    • Serial PK sampling for noncompartmental analysis was included in all cohorts of GEN501 part 1 and in one daratumumab 16 mg/kg cohort of GEN501 part 2.
    • Sparse PK sampling for PPK modeling was included for all patients in both studies.

Results

PK Observations
  • PK data were available from 100 patients in GEN501 and 123 patients in SIRIUS.
    • All concentrations of daratumumab were below the limit of quantification in patients who received daratumumab 0.005 mg/kg and 0.05 mg/kg.
  • PK parameters from the first and last (7th) full Infusions in GEN501 part 1 are detailed in Table: PK Parameters From the First and Last (7th) Full Infusions in GEN501 Part 1.
    • After the first full infusion, the maximum concentration (Cmax) was nearly dose proportional for doses of 1 to 24 mg/kg and increased greater than dose-proportionally after the last (7th) dose.
    • After the first full infusion, Cmax increased in a ratio of 1:2:4:8:20:25 as dose increased in a ratio of 1:2:4:8:16:24.
    • The area under the curve (AUC) increased greater than dose-proportionally after the first and last doses.
    • Clearance decreased with increasing dose and with multiple doses.

PK Parameters From the First and Last (7th) Full Infusions in GEN501 Part 13

Daratumumab
0.1 mg/kg
(n=6)

0.5 mg/kg
(n=3)

1 mg/kg
(n=6)

2 mg/kg
(n=3)

4 mg/kg
(n=3)

8 mg/kg
(n=3)

16 mg/kg
(n=3)

24 mg/kg
(n=3)

First full infusion
Cmax (µg/mL)
   N
6
3
6
3
3
3
3
3
   Mean
0.3
4.8
20.3
38.1
83.4
153.6
405.8
500.1
   SD
0.3
3.7
5.9
7.4
16.0
40.8
72.5
80.4
   CV (%)
91.7
76.7
28.9
19.3
19.2
26.6
17.9
16.1
AUCinf (µg•h/mL)
   N
0
1
5
3
3
3
3
3
   Mean
-
313.3
977.2
1927.1
10,062.9
27,916.4
56,893.6
97,175.7
   SD
-
-
758.1
373.3
6886.0
16,155.7
22,030.4
39,899.9
   CV (%)
-
-
77.6
19.4
68.4
57.9
38.7
41.1
CL (mL/h/kg)
   N
0
1
5
3
3
3
3
3
   Mean
-
1.6
1.5
1.1
0.7
0.4
0.3
0.3
   SD
-
-
1.0
0.2
0.8
0.3
0.1
0.2
   CV (%)
-
-
64.0
19.1
102.7
77.7
42.4
51.7
t1/2 (h)
   N
0
1
5
3
3
3
3
3
   Mean
-
20.0
28.3
25.6
91.5
131.8
109.9
154.7
   SD
-
-
17.9
5.6
59.9
68.2
42.1
36.5
   CV (%)
-
-
63.1
21.9
65.5
51.7
38.3
23.6
Last full infusion
Cmax (µg/mL)
   N
1
3
2
1
2
3
2
2
   Mean
0.00
6.8
20.2
39.3
218.5
426.6
993.7
1163.3
   SD
-
3.8
11.9
-
101.3
176.6
127.0
334.0
   CV (%)
-
55.6
58.9
-
46.3
41.4
12.8
28.7
AUCinf (µg•h/mL)
   N
0
3
2
1
2
2
1
2
   Mean
-
179.7
1345.2
4231.7
138,149.1
186,611.9
371,159.3
1,018,233.5
   SD
-
220.8
1620.3
-
163,370.0
90,617.6
-
1,029,108.4
   CV (%)
-
122.9
120.4
-
118.3
48.6
-
101.1
CL (mL/h/kg)
   N
0
3
2
1
2
3
1
2
   Mean
-
6.7
2.3
0.6
0.2
0.2
0.1
0.2
   SD
-
6.2
2.6
-
0.1
0.1
-
0.1
   CV (%)
-
92.0
112.5
-
64.7
50.0
-
46.5
t1/2 (h)
   N
0
3
2
1
2
2
1
2
   Mean
-
12.7
35.7
72.1
396.5
289.5
215.3
586.6
   SD
-
12.3
37.6
-
408.1
121.9
-
486.8
   CV (%)
-
97.0
105.2
-
102.9
42.1
-
83.0
Abbreviations: AUCinf, area under the concentration versus time curve from time 0 extrapolated to infinity; CL, clearance; Cmax, maximum concentration; CV, coefficient of variation; PK, pharmacokinetic; SD, standard deviation; t1/2, half-life.

Summary of Daratumumab PK Parameters Following the First Full Infusion in GEN501 Part 23

Daratumumab
8 mg/kg
(n=30)

16 mg/kg
(n=42)

Cmax (µg/mL)
   N
28
40
   Mean (SD)
133.5 (32.5)
263.4 (92.0)
   CV (%)
24.3
34.9
AUC0-7 days (µg•h/mL)
   N
0
20
   Mean (SD)
-
25,123.3 (10,851.5)
   CV (%)
-
43.2
t1/2 (h)
   N
0
19
   Mean (SD)
-
216.1 (104.0)
   CV (%)
-
48.2
CL (mL/h/kg)
   N
0
19
   Mean (SD)
-
0.4 (0.4)
   CV (%)
-
100.6
Vd (mL/kg)
   N
0
19
   Mean (SD)
-
90.2 (43.40)
   CV (%)
-
48.1
Abbreviations: AUC0-7 days area under the concentration-time curve from time zero to 7 days; CL, clearance; Cmax, maximum concentration; CV, coefficient of variation; PK, pharmacokinetic; SD, standard deviation; t1/2, half-life; Vd, volume of distribution.

Summary of Daratumumab PK Parameters Following the First Full Infusion in the SIRIUS Study3
Daratumumab
8 mg/kg
(n=18)

Cmax (µg/mL)
   N
18
   Mean (SD)
138.7 (34.9)
   CV (%)
25.1
AUCinf (µg•h/mL)
   N
15
   Mean (SD)
21,070.0 (13,514.3)
   CV (%)
64.1
t1/2 (h)
   N
15
   Mean (SD)
120.7 (105.8)
   CV (%)
87.7
CL (mL/h/kg)
   N
15
   Mean (SD)
0.5 (0.3)
   CV (%)
49.0
Vd (mL/kg)
   N
15
   Mean (SD)
62.0 (18.4)
   CV (%)
29.7
Abbreviations: AUCinf, area under the concentration-time curve from time zero extrapolated to infinity; CL, clearance; Cmax, maximum concentration; CV, coefficient of variation; PK, pharmacokinetic; SD, standard deviation; t1/2, half-life; Vd, volume of distribution.
  • The majority of patients exhibited a decrease in paraprotein from baseline.
    • GEN501: >50% reduction in 46% of patients receiving daratumumab 16 mg/kg; >90% reduction in 24% of patients receiving daratumumab 16 mg/kg.
    • SIRIUS: >50% reduction in 38% of patients receiving daratumumab 16 mg/kg; >90% reduction in 16% of patients receiving daratumumab 16 mg/kg.
    • There was a significant positive correlation between maximum reduction in paraprotein and daratumumab exposure.

PPK Modeling of Daratumumab from the GEN501 and SIRIUS Studies

Yan et al (2015)4 reported the results of a PPK model showing that daratumumab clearance was concentration- and time-dependent and that nonlinear clearance decreased over time.

Results

  • A total of 2572 samples from 223 patients were evaluated (n=150 received daratumumab 16 mg/kg).
  • Data were best described by a 2-compartment PPK model with parallel linear and nonlinear Michaelis-Menten eliminations.
  • The model suggested that nonlinear (target-mediated) clearance of daratumumab was concentration- and time-dependent, potentially due to saturation and depletion of the target.
  • At steady state, the target-mediated clearance of daratumumab approached 0. By the end of the weekly dosing period, nonspecific (linear) clearance became the dominant clearance pathway.
  • Concentration- and time-dependency of daratumumab clearance suggested that dynamics of target/tumor burden significantly influenced daratumumab disposition.
  • The PPK model predicted that a concentration of 21.4 µg/mL and 236 µg/mL would be needed to achieve 90% and 99% target saturation, respectively.
  • At the end of every 4 weeks dosing, 82% and 67% of patients achieved >90% target saturation at doses of daratumumab 16 mg/kg and 8 mg/kg, respectively.
  • Exposure to daratumumab was relatively consistent across the range of body weights of patients after administration on a mg/kg basis.
  • Age, race, renal impairment, and mild hepatic impairment had neither statistically significant nor clinically relevant effects on exposure to daratumumab.
  • Exposure was consistent across the different subgroups for PS (ECOG), refractory status, and number of prior lines of therapy.
  • Baseline albumin levels, type of myeloma (IgG vs nonIgG), and sex had a statistically significant effect on daratumumab PK. However, additional analyses showed that these covariates did not have clinically relevant impacts on efficacy or safety profiles.

Population Pharmacokinetic Study

Xu et al (2016, 2018)5,6 conducted PPK and exposure-response analyses for daratumumab in combination with standard therapies for multiple myeloma in patients previously treated with 1 or more lines of therapy.

Study Design/Methods

  • PPK analyses were performed on pooled datasets from 4 clinical trials of daratumumab in combination with standard therapies as follows5,6:
    • GEN503 - Daratumumab in combination with lenalidomide and dexamethasone (Rd)
    • MMY1001 - Daratumumab in combination with bortezomib and dexamethasone (Vd); bortezomib, melphalan and prednisone (VMP); bortezomib, thalidomide, and dexamethasone (VTd); or pomalidomide and dexamethasone [Pd]
    • POLLUX - Daratumumab plus Rd (DRd)
    • CASTOR - Daratumumab plus Vd (DVd)

Results

  • A total of 4,426 measurable PK samples from 694 patients were included in the PPK dataset (684 of these patients received daratumumab 16 mg/kg).
  • The PK of daratumumab were similar between the monotherapy and combination therapy studies.
    • Data were adequately described by a 2-compartment PPK model with parallel linear and nonlinear Michaelis-Menton eliminations.
    • Model-derived half-life was 23.3±11.8 days in the combination studies and 18±9.0 days in the monotherapy studies.
    • Steady state was achieved at approximately 5 months in both the combination and monotherapy studies.
    • Daratumumab concentrations were statistically lower in patients with abnormal albumin levels and immunoglobulin G myeloma but the impact was small and not clinically relevant.
    • Age, sex, race, region, renal and hepatic impairment, type of combination therapy, ECOG status, refractory status, and number of prior lines of therapy had no clinically important effects on exposure to daratumumab.
    • Clearance and volume of distribution of daratumumab increased with increasing body weight but exposure was consistent when administered on a mg/kg basis.
  • Risk of disease progression and death decreased with increasing daratumumab exposure.
  • There was no apparent relationship between daratumumab exposure and infusion-related reactions, thrombocytopenia, anemia, neutropenia, lymphopenia, or infection across all combination regimens.

PK Analysis and PPK Simulation

Xu et al (2018, 2020)7,8 conducted PK analyses of data collected from the phase 1b MMY1001 study regarding splitting the first treatment cycle dose of daratumumab 16 mg/kg into 2 separate infusions of 8 mg/kg on days 1 and 2 as compared to single first dose regimen. PPK analysis and computer simulations were also performed comparing split first dose and single first dose regimens using data collected from studies that utilized various daratumumab combination dosing schedules and indications.

Study Design/Methods

PK Analysis
  • PK analysis were performed using MMY1001 clinical PK data from 3 cohorts (n=107):
    • In cohorts 1 and 2 (n=97), patients received the first daratumumab dose as a split first dose of 8 mg/kg on cycle 1 day 1 (C1D1) and on cycle 1 day 2 (C1D2).
      • 75 patients were in the daratumumab in combination with carfilzomib and dexamethasone (DKd) cohort and 22 patients were in the daratumumab in combination with carfilzomib, lenalidomide, dexamethasone (DKRd) cohort.
    • In cohort 3 (n=10), patients received daratumumab as a single first dose regimen of 16 mg/kg on C1D1 in the DKd cohort.
    • Observed PK data were summarized based on timepoint.
  • DKd and DKRd cohorts (all patients): Pre- and post-infusion daratumumab serum samples were collected on day 1 of cycle 1 through cycle 4, and 3 and 9 weeks post-treatment.
    • DKd and DKRd split first dose cohort: Pre- and post-infusion serum samples were also collected on C1D2.
PPK Simulations
  • Simulations and modeling were used to compare the PK profile of daratumumab split first dose regimen (8 mg/kg on C1D1 and C1D2) with single first dose regimens (16 mg/kg on C1D1) using individual PK parameters from 7 daratumumab multiple myeloma studies:
    • Daratumumab monotherapy (GEN501 and SIRIUS) and daratumumab in combination with lenalidomide and dexamethasone (DRd; GEN503 and POLLUX), pomalidomide and dexamethasone (DPd; MMY1001), DKd (MMY1001), DKRd (MMY1001), bortezomib and dexamethasone (DVd; MMY1001 and CASTOR) and bortezomib, melphalan and prednisone (DVMP; MMY1001 and ALCYONE).
  • Simulations were conducted with the following dosing regimens and schedules:
    • Group 1: daratumumab monotherapy, DRd, DPd, DKd, DKRd: 16 mg/kg once weekly for 8 weeks, every 2 weeks for 16 weeks, and every 4 weeks thereafter
    • Group 2: DVd: 16 mg/kg once weekly for 9 weeks, every 3 weeks for 15 weeks, and thereafter
    • Group 3: DVMP: 16 mg/kg once weekly for 6 weeks, every 3 weeks for 48 weeks, and every 4 weeks thereafter

Results

Safety
  • MMY1001 preliminary observations did not demonstrate an increased rate of infusion-related reactions (IRRs) when comparing split first dose and standard first dose.12
    • The DKd arm of MMY1001 noted the rate of IRRs to be 43% (n=32) in the split first dose group and 50% (n=5) in the single first dose group.
PK Analysis
  • On C1D1, mean (standard deviation [SD]) split first dose (8 mg/kg) daratumumab post-infusion concentrations were lower (159 [47] µg/mL) than single first dose (16 mg/kg) post-infusion concentrations (321 [49] µg/mL).
  • Similar mean (SD) daratumumab concentrations following administration of the first total dose of 16 mg/kg were noted in both the split first dose cohort (C1D2 post-infusion 257 [68.6] µg/mL) and the single first dose cohort (C1D1 post-infusion 321 [49.0] µg/mL).
  • Following weekly dosing, similar mean (SD) cycle 3 day 1 (C3D1) trough concentrations (Ctrough) were noted in both the split first dose cohort (606 [237] µg/mL) and the single first dose cohort (517 [137] µg/mL). See Figure Mean Daratumumab Serum Concentrations (µg/mL) for the Single and Split First Dose of Daratumumab Among PK-evaluable Patients who Received DKd and DKRd in MMY1001 Study

Mean Daratumumab Serum Concentrations (µg/mL) for the Single and Split First Dose of Daratumumab Among PK-evaluable Patients who Received D-Kd and D-KRd in MMY1001 Study8

Abbreviations: C, cycle; D, day; D-Kd, daratumumab + carfilzomib + dexamethasone; D-KRd, daratumumab + carfilzomib + lenalidomide + dexamethasone; DARA, daratumumab; PK, pharmacokinetics.


Median Daratumumab Serum Concentrations for the Split and Single First Dose of Daratumumab Among PK-evaluable Patients who Received DKd and DKRd in the MMY1001 Study8
Sampling Time Pointa,b
DKd
DKRd
Split Dose
8 mg/kg
(n=22)

Combined
Split Dose
(n=97)

Single Dose
16 mg/kg
(n=10)

Split Dose
8 mg/kg
(n=75)

C1D1 post-infusion, median (range), µg/mL
n=8
319.2
(237.5-394.7)

n=71
151.5
(82.5-345.0)

n=15
177.8
(121.9-215.7)

n=86
156.7
(82.5-345.0)

   CV (%)
15.3
31.5
16.8
29.3
C1D2 pre-infusion, median (range), µg/mL
n=NA
-

n=65
110.5
(0.0-284.9)

n=16
118.0
(61.2-169.2)

n=81
111.6
(0.0-284.9)

   CV (%)
-
37.9
24.5
35.4
C1D2 post-infusion, median (range), µg/mL
n=NA
-

n=69
254.9
(125.8-435.5)

n=18
277.2
(164.0-341.8)

n=87
256.8
(125.8-435.5)

   CV (%)
-
28.2
20.8
26.7
C2D1 pre-infusion, median (range), µg/mL
n=10
335.8
(186.6-556.4)

n=63
380.7
(0.0-721.6)

n=21
329.8
(112.1-473.4)

n=84
354.7
(0.0-721.6)

   CV (%)
34.5
49.4
32.9
47.0
C2D1 post-infusion, median (range), µg/mL
n=9
726.6
(523.1-911.6)

n=64
688.6
(0.0-1202.4)

n=15
692.4
(458.8-961.0)

n=79
688.9
(0.0-1202.4)

   CV (%)
22.1
36.4
23.1
34.3
C3D1 pre-infusion, median (range), µg/mL
n=9
463.2
(355.9-792.9)

n=52
663.9
(57.7-1110.7)

n=19
575.1
(237.9-825.5)

n=71
639.2
(57.7-1110.7)

   CV (%)
26.5
41.4
30.7
39.1
C3D1 post-infusion, median (range), µg/mL
n=9
844.1
(725.4-1176.0)

n=52
916.0
(36.9-1711.3)

n=14
939.3
(638.4-1301.0)

n=66
926.0
(36.9-1711.3)

   CV (%)
18.9
36.8
17.9
33.5
C4D1 pre-infusion, median (range), µg/mL
n=7
509.1
(291.2-743.5)

n=24
613.0
(92.3-1019.3)

n=21
457.3
(146.1-768.1)

n=45
523.0
(92.3-1019.3)

   CV (%)
30.9
41.8
33.2
39.2
C4D1 post-infusion, median (range), µg/mL
n=8
918.6
(646.5-1142.6)

n=24
962.0
(347.0-1630.2)

n=11
939.4
(776.6-1205.0)

n=35
939.4
(347.0-1630.2)

   CV (%)
19.2
31.3
15.3
27.0
Abbreviations: C, cycle; CV, coefficient of variation; D, day; DKd, daratumumab/carfilzomib/dexamethasone;
DKRd, daratumumab/carfilzomib/lenalidomide/dexamethasone; PK, pharmacokinetics; SD, standard deviation; NA, not applicable.
aFor post-infusion, serum samples were collected within 5 minutes after the end of infusion.
bFor pre-infusion, serum samples were collected within 2 hours before the start of the infusion or administration of the backbone medications.

PPK Analysis

Simulated Concentration-time Profiles for the Split and Single First Dose of Daratumumab 16 mg/kg in Patients Who Received Daratumumab Monotherapy, D-Rd, D-Kd, D-KRd, and D-Pd (Group 1); D-Vd (Group 2); and D-VMP (Group 3) Regimens7

Abbreviations: Dara, daratumumab; D-Kd, daratumumab + carfilzomib + dexamethasone; D-KRd, daratumumab + carfilzomib + lenalidomide + dexamethasone; D-Pd, daratumumab + pomalidomide + dexamethasone; D-Rd, daratumumab + lenalidomide + dexamethasone; D-Vd, daratumumab + bortezomib + dexamethasone; D-VMP, daratumumab + bortezomib + melphalan + prednisone; DARA, daratumumab.
Note: The red solid and blue dashed lines represent the median, and the shaded regions are bounded by the 2.5th and 97.5th percentiles of the simulation.

  • After C1D2, pre-infusion Ctrough and post-infusion maximum concentration values were comparable between the split first dose and single first dose infusions for both monotherapy and combination regimens.
  • Following the C1D2 split dose (8 mg/kg), concentration differences were reduced to ≤1% between the 2 dosing regimens.

LITERATURE SEARCH

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 22 October 2026.

 

References

1 Data on File. Daratumumab Intravenous Formulation Company Core Data Sheet (CCDS). Janssen Research & Development, LLC. EDMS-ERI-78724630; 2026.  
2 Clemens PL, Yan X, Puchalski T, et al. Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma (MM) after prior proteasome inhibitor (PI) and immunomodulatory drug (IMiD) treatment. Poster presented at: The 15th International Myeloma Workshop; September 23-26, 2015; Rome, Italy.  
3 Clemens PL, Yan X, Lokhorst HM, et al. Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment. Clin Pharmacokinet. 2017;56(8):915-924.  
4 Yan X, Clemens PL, Puchalski T, et al. Target-mediated drug disposition of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitors and immunomodulatory drugs: a population pharmacokinetic analysis. Poster 4222 presented at: The 57th American Society of Hematology (ASH) Annual Meeting & Exposition; December 5-8, 2015; Orlando, Florida.  
5 Xu XS, Liao S, Dimopoulos MA, et al. Population pharmacokinetics and exposure-response analyses for daratumumab combination therapies for patients with multiple myeloma (MM) who have received 1 or more prior lines of therapy. Poster 3340 presented at: The 58th American Society of Hematology (ASH) Annual Meeting Exposition; December 3-6, 2016; San Diego, CA.  
6 Xu X, Dimopoulos M, Sonneveld P, et al. Pharmacokinetics and exposure-response analyses of daratumumab in combination therapy regimens for patients with multiple myeloma. Adv Ther. 2018;35:1859-1872.  
7 Xu X, Moreau P, Usmani S, et al. Split first dose administration of daratumumab for the treatment of patients with multiple myeloma (MM): clinical pharmacology and population pharmacokinetic (PK) analyses. Poster presented at: 60th American Society of Hematology (ASH) Annual Meeting & Exposition; December 1-4, 2018; San Diego, CA.  
8 Xu XS, Moreau P, Usmani SZ, et al. Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. Adv Ther. 2020;37(4):1464-1478.  
9 Mascelli MA, Zhou H, Sweet R, et al. Molecular, Biologic, and Pharmacokinetic Properties of Monoclonal Antibodies: Impact of These Parameters on Early Clinical Development. J Clin Pharmacol. 2007;47(5):553-565.  
10 Tabrizi MA, Tseng CML, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11(2-Jan):81-88.  
11 Data on File. Daratumumab. Summary of Clinical Pharmacology Studies, Relapsed and Refractory Multiple Myeloma. Janssen Research & Development, LLC.  EDMS-ERI-97995815; 2015.  
12 Chari A, Martinez-Lopez J, Mateos M, et al. Daratumumab in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide-refractory patients with relapsed multiple myeloma: subgroup analysis of MMY1001. Oral presentation presented at: The Annual Meeting of the American Society of Clinical Oncology (ASCO); June 1-5, 2018; Chicago, IL.  

Would you like to clear and leave your conversation? Message history will be lost.